ArticleJAC-antimicrobial resistance2026
Can a host-response bacterial-viral classifier safely guide antibiotic avoidance in COVID-19? A diagnostic accuracy study in hospitalized adults.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: The MeMed BV Methods: We included adults with PCR-confirmed SARS-CoV-2 infection from two prospective Norwegian cohorts (October 2020-April 2023). The reference standard for true viral infection was a composite safety outcome: 30-day survival, no readmission within 30 days, and no antibiotic exposure before, during, or after hospitalization. MeMed BV performance was assessed using sensitivity, specificity, predictive values, and area under the ROC curve (AUC). Results: Of 90 patients, 28 (31%) met the reference standard for safe antibiotic avoidance. Median MeMed BV scores were 38 (IQR 1-66) in the safely managed group versus 96 (IQR 78-99) in others ( Conclusions: In hospitalized adults with COVID-19, MeMed BV showed reasonable specificity but limited sensitivity for identifying patients who could safely avoid antibiotics, with performance considerably lower than that observed in pre-COVID studies. These findings highlight the need for context-specific validation of host-response diagnostics.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.